Skip to content

Autism Early Diagnosis

Autism Early Diagnosis

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073230
Enrollment
Unknown
Registered
2023-07-04
Start date
2023-07-05
Completion date
Unknown
Last updated
2023-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder

Interventions

ASD group (the participant children diagnosed with ASD at baseline or follow-up):The exploratory intervention experiment is the fourth part of the project. Based on the research results of the first p
High-risk ASD group (below the DSM-5 diagnostic threshold for ASD at baseline AND follow-up) :None
Control group:None

Sponsors

Shenzhen Children's Hostipal
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1.5 Years to 3 Years

Inclusion criteria

Inclusion criteria: High-risk ASD group inclusion criteria: 1) Positive family history: grandparents, father, mother or sibling was diagnosed ASD; 2) Exhibit the core symptoms of the DSM-5 diagnostic criteria for ASD (i.e., abnormalities in attention, repetitive stereotyped behaviors, or narrow interests) 3) M-CAHT-R screening score =3 points; 1) ~3) Either match and 4) Normal vision. Control group inclusion criteria: both match 1) No obvious abnormality in birth history and personal development history: full-term birth, birth weight =2.5kg, no history of hypoxia rescue; No significant abnormalities in previous developmental screening; 2) Negative family history: grandparents, father, mother, and siblings have no ASD, language delay, developmental delay, intellectual disability, ADHD; 3) no core symptoms of ASD in the DSM-5 diagnostic criteria (i.e., abnormalities in attention, repetitive stereotyped behaviors, or narrow interests); 4) M-CAHT-R screening =2 points; 5) Normal vision.

Exclusion criteria

Exclusion criteria: High-risk ASD group: 1) A clear history of craniocerebral trauma, a history of serious physical diseases, and a clear etiological diagnosis of neurodevelopmental disorders; 2) Those who have taken neuropsychiatric drugs in the past six months; 3) Contraindications of magnetic resonance detection. Control group: 1) Clear history of craniocerebral trauma, history of serious physical diseases, epilepsy, and use of neuropsychiatric drugs in the past six months, 2) Contraindications of magnetic resonance detection.

Design outcomes

Primary

MeasureTime frame
behavioral measures: CARS, ADOS-2,M-CHAT;eye tracking measures: first fixation time, fixation duration, and percentage of fixation time for each area of interest;EEG measures: latency and amplitude of EEG components related to emotional stimuli;

Secondary

MeasureTime frame
developmental and adaptive behavior measures:Griffiths Mental Development Scales or Gesell scale, Adaptive Behavior Assessment System, (ABAS-II);

Countries

China

Contacts

Public ContactBinrang Yang

Shenzhen Children's Hostipal

ybinrang@163.com+86 189 3869 1619

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026